Recall: D-0552-2023

Class II - Potentially Harmful

Class IIClassification

2023-03-16Initiated

OngoingStatus

Northwind Pharmaceuticals LLCFirm

Product

Glimepiride Tablets, USP 4mg, packaged in a) 30-count bottles (NDC 51655-120-52), and b) 90-count bottles (NDC 51655-120-26), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.

Reason

CGMP Deviations

Distribution

Nationwide with the United States

Source: FDA drug enforcement report via openFDA (Voluntary: Firm initiated). If you take this product, talk to your pharmacist or doctor before stopping it.